- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01312597
Effects of Flavonoids on Cognitive Performance in Healthy Young Adults
November 22, 2011 updated by: Jeremy Paul Edward Spencer, University of Reading
The purpose of this study is to investigate changes in cerebral blood flow, blood flavonoid levels, brain-derived neurotrophic factor, vascular reactivity and cognitive performance in young adults as a result of acute administration of a fruit-derived flavonoid-rich or flavonoid-poor drink.
Study Overview
Detailed Description
There has recently been an increasing interest in the potential of flavonoids, plant derived compounds found in foods such as fruit and vegetables, to ameliorate age-related cognitive decline.
Research suggests that flavonoids improve memory and learning, possibly as a result of their anti-oxidant, anti-inflammatory and neuroprotective effects for example by increasing cerebral blood flow, protecting vulnerable neurons, enhancing existing neuronal function or by stimulating neuronal function.
The research will initially involve a randomised cross-over human dietary intervention trial using two flavonoid-rich drinks (flavanone-rich and flavanone-poor) to investigate changes in cerebral blood flow in young adults (n=6; age range 18-30 years).
Changes in cognitive performance and measures of serum BDNF levels will then be investigated in a second randomised cross-over trial using the intervention drink showing the greatest effect on cerebral blood flow in young adults (n=24; age range 18-30 years) and using a range of sensitive tests of executive function.
The study is designed to measure acute effects of types of flavonoid supplementation and, as well as the primary cognitive outcome, will assess flavonoid/metabolite and BDNF (brain-derived neurotrophic factor) levels in blood and changes in vascular reactivity.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Berkshire
-
Reading, Berkshire, United Kingdom, RG6 6AP
- University of Reading
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 30 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- MMSE between 26 and 30
- 18-30 years of age
- Native or good English speaker
- Normal BMI/body fat composition
- No significant vision, hearing or language problems
- Able to consume the beverages
Exclusion Criteria:
- Any form of disease/major mental illness/chronic fatigue syndrome
- On medication for hypertension/elevated lipids/diabetes
- On medication known to impact endothelial function
- Gall bladder/gastrointestinal abnormalities
- Sensitivity to orange or apple
- High consumer of fruit, vegetables, fruit beverages
- High consumer of caffeine or alcohol
- Consumer of illegal substances
- Vegetarian/vegan/other dieter/vigorous exerciser
- Use of antibiotics in the previous 8 weeks
- Consumer of dietary supplements
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fruit beverage
|
500ml fruit juice beverage, single dose per visit
Other Names:
|
Experimental: Control beverage
|
500ml fruit juice beverage, single dose per visit
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Executive function
Time Frame: change in attention between baseline and 2h
|
45-minute computer-based test battery of executive function tasks administered twice per visit day, at 0 hours (baseline) and 2 hours post-intervention.
Visit days are at least one week apart.
|
change in attention between baseline and 2h
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cerebral blood flow
Time Frame: change in attention between baseline and 2h
|
Non-invasive fMRI (arterial spin labelling) is conducted pre- and post-intervention at 3 time-points: 0 (baseline), and 2 and 5 hours post-intervention on 3 study days at least one week apart
|
change in attention between baseline and 2h
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2010
Primary Completion (Actual)
August 1, 2011
Study Completion (Actual)
September 1, 2011
Study Registration Dates
First Submitted
March 9, 2011
First Submitted That Met QC Criteria
March 9, 2011
First Posted (Estimate)
March 10, 2011
Study Record Updates
Last Update Posted (Estimate)
November 23, 2011
Last Update Submitted That Met QC Criteria
November 22, 2011
Last Verified
November 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UReading-2011-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neurodegeneration
-
LMU KlinikumSeventh Framework Programme; NBIA AllianceRecruitingNeurodegeneration With Brain Iron Accumulation (NBIA) | Pantothenate Kinase-associated Neurodegeneration (PKAN) | Aceruloplasminemia | Beta-Propeller Protein-Associated Neurodegeneration (BPAN) | Mitochondrial Membrane Protein Associated Neurodegeneration (MPAN) | Fatty Acid Hydroxylase-associated... and other conditionsCanada, Czechia, Germany, Italy, Netherlands, Poland, Serbia, Spain
-
Seoul National University HospitalTerminatedBiomarker With Neurodegeneration PatientsKorea, Republic of
-
Susan J. HayflickOregon Health and Science UniversityRecruitingNeurodegeneration With Brain Iron Accumulation (NBIA)United States
-
University Hospital, BordeauxInstitut National de la Santé Et de la Recherche Médicale, FranceCompletedNeurodegeneration With Brain Iron Accumulation (NBIA)France
-
University of PennsylvaniaChildren's Hospital of PhiladelphiaCompletedGeneral Anesthesia | NeurodegenerationUnited States
-
Susan J. HayflickOregon Health and Science University; Oregon Clinical and Translational Research...CompletedPantothenate Kinase-associated Neurodegeneration (PKAN)United States
-
Thiel, Alexander, M.D.Canadian Institutes of Health Research (CIHR); University of AlbertaNot yet recruiting
-
Turku University HospitalUnknownGlymphatic System | NeurodegenerationFinland
-
University College, LondonUnknownMitochondrial Diseases | Dystonia, Familial | Sporadic Dystonia | Parkinson Disease, Juvenile | Neurodegeneration With Brain Iron Accumulation 5
-
Ente Ospedaliero Ospedali GallieraActive, not recruitingIron Overload | Neurodegenerative DiseaseItaly
Clinical Trials on Fruit juice beverage
-
PepsiCo Global R&DCompletedGlycemic IndexUnited States
-
Universidade Nova de LisboaCompleted
-
Northumbria UniversityCompletedCognitive Impairment | Cerebrovascular CirculationUnited Kingdom
-
Birmingham Community Healthcare NHSNSA, LLCCompleted
-
USDA Grand Forks Human Nutrition Research CenterRecruitingOverweightUnited States
-
Valio LtdUniversity of Virginia; University of Helsinki; Medcare LtdCompletedRespiratory Tract Infections [C08.730]United States
-
Kansas State UniversityCompletedMetabolic SyndromeUnited States
-
Inonu UniversityCompleted
-
International Medical UniversityTate & LyleCompleted